IFM Investors Pty Ltd Grows Stock Position in Catalent, Inc. (NYSE:CTLT)

IFM Investors Pty Ltd lifted its stake in Catalent, Inc. (NYSE:CTLT) by 10.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,543 shares of the company’s stock after buying an additional 3,372 shares during the period. IFM Investors Pty Ltd’s holdings in Catalent were worth $2,006,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Czech National Bank increased its holdings in Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares during the period. BNP Paribas Asset Management Holding S.A. boosted its position in Catalent by 1.9% during the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after acquiring an additional 328 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in Catalent by 6.2% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after acquiring an additional 331 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Catalent by 2.6% during the 3rd quarter. Teacher Retirement System of Texas now owns 13,966 shares of the company’s stock worth $636,000 after acquiring an additional 350 shares during the period. Finally, Arizona State Retirement System grew its holdings in shares of Catalent by 0.7% during the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock worth $2,226,000 after acquiring an additional 365 shares during the period.

Catalent Stock Performance

Shares of NYSE CTLT traded up $0.12 during midday trading on Friday, hitting $55.92. 2,846,393 shares of the stock traded hands, compared to its average volume of 1,545,863. The firm has a 50-day moving average of $56.68 and a two-hundred day moving average of $48.70. The firm has a market capitalization of $10.12 billion, a P/E ratio of -8.22, a PEG ratio of 6.03 and a beta of 1.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business posted $0.62 earnings per share. Catalent’s revenue for the quarter was down 10.2% compared to the same quarter last year. On average, equities analysts forecast that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Ratings Changes

CTLT has been the topic of a number of research analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, February 20th. Stephens reiterated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Barclays upped their target price on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. UBS Group restated a “neutral” rating and issued a $63.50 price target (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, StockNews.com began coverage on Catalent in a research note on Saturday. They issued a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.